by Dennis Crouch Teva Pharmaceuticals, LLC  v. Corcept Therapeutics, Inc., Dockt No. 21-1360 (Fed. Cir. 2021) This is an interesting pro-pharma obviousness decision coming out of the PTAB regarding obviousness of particular drug dosages.  Here, the particular drug was known to work well, but there were concerns about drug safety.  And, there were a couple of … Continue reading Federal Circuit Draws a Hard Line Against “Obvious to Try” Analysis